Effects of 6-month eicosapentaenoic acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin secretion ability, and concomitant endothelial dysfunction among newly-diagnosed impaired glucose metabolism patients with coronary artery disease. An open label, single blinded, prospective randomized controlled trial

Background Recent experimental studies have revealed that n-3 fatty acids, such as eicosapentaenoic acid (EPA) regulate postprandialinsulin secretion, and correct postprandialglucose and lipid abnormalities. However, the effects of 6-month EPA treatment on postprandialhyperglycemia and hyperlipidemia, insulin secretion, and concomitant endothelial dysfunctionremain unknown in patients with impaired glucose metabolism (IGM) and coronary artery disease (CAD).